Influence of cytokines on the expression of Fas ligand and CD44 splice variants in colon carcinoma cells

Tumor Biology

Volumn 20, Issue 6, 1999, Pages 294-303

  Wimmenauer, Stephan ^a,c   Steiert, A ^a   Wolff Vorbeck, G ^a   Xing, B C ^a   Baier, P K ^a   Ruckauer K D ^a   Kirste, G ^a   Von Kleist, S ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NONE   (Germany)

Author keywords

Adenocarcinomas, colorectum; Apoptosis; Cellular adhesion molecules; Fas; Fas ligand

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; FAS LIGAND; HERMES ANTIGEN; MEMBRANE PROTEIN;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CARCINOMA CELL; COLON CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0032750234     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030093     Document Type: Article

References (20)

1. Suda T, Takahashi T, Goldstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
2. Hanabuchy S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Yonehara S, Yagita H, Okumura K: Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994;91:4930-4934.
3. Russell JH, Rush B, Weaver C, Wang R: Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci USA 1993;90:4409-4413.
4. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
5. Zeytun A, Hassuneh M, Nagarkatti M, Nagerkatti PS: Fas-Fas ligand-based interactions between tumor cells and tumor specific cytotoxic T lymphocytes: A lethal two way street. Blood 1997;90:1952-1959.
6. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;84:1075-1082.
7. Lens SM, Tesselaar K, den Drijver BF, van Oers MH, van Lier RA: A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J Immunol 1996;156: 507-514.
8. Medvedev AE, Johnson AC, Haux J, Steinkjer B, Egeberg K, Lynch DH, Sudan A, Espevik T: Regulation of Fas and Fas-ligand expression in NK-cells by cytokines and involvement of the Fas ligand in NK/LAK cell mediated cytotoxicity. Cytokine 1997;9:394-404.
9. Strand S, Hofman WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion. Nat Med 1996;2:1361-1366.
10. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J-C, Tschopp J: Melanoma cell expression of Fas (APO-1/CD95) ligand: Implications for tumor escape. Science 1996;274: 1363-1366.
11. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H: Expression of fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997;94: 6420-6425.
12. Ortizarduan A, Danoff TM, Kalluri R, Gonzalezcuadrado S, Karp SL, Elkkon K, Egido J, Neilson EG: Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol 1996;40: 1193-1201.
13. Tanaka M, Takashi S, Haze K, Nakumara N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ogha S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med 1996;2:317-322.
14. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J Exp Med 1996;184:429-440.
15. Fiers W: Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
16. Vassalli P: The pathophysiology of tumor necrosis factor. Annu Rev Immunol 1992;10:411-452.
17. Wimmenauer S, Keller H, Rückauer KD, Rahner S, Wolff-Vorbeck G, Kirste G, von Kleist S, Farthmann EH: Expression of CD44, ICAM-1 and N-CAM in colorectal cancer. Correlation with the tumor stage and the phenotypical characteristics of tumor-infiltrating lymphocytes. Anticancer Res 1997;17: 2395-2400.
18. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf Günther R, van den Berg FM, Ponta H, Herrlich P, Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-4756.
19. Dämmrich LA, Vollmers HP, Heider KH, Müller-Hermelik HK: Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading. J Mol Med 1995;73:395-401.
20. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE: Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell mediated cytotoxicity. J Immunol 1991;147:4398-4401.